Teleflex/Genzyme Biosurgery
This article was originally published in The Gray Sheet
Executive Summary
Plymouth Meeting, Penn. firm gains minimally invasive heart surgery and vein harvesting systems, aortic punch product lines, and cardiovascular and valve suture devices, through purchase of Genzyme Biosurgery's cardiothoracic devices business. Teleflex will pay Genzyme $32.4 mil. in cash and $8 mil. in assumed trade obligations. The cardiothoracic product lines earned $76 mil. in revenues in 2002...